The Molecular Biomarker Revolution in Metastatic NSCLC
Session from American Society for Clinical Pathology (ASCP) 2022 annual meeting discussing the latest on emerging Biomarkers, Immuno-oncology resistance mechanisms and treatment options (e.g. therapies involving CTLA-4 inhibitors) in metastatic NSCLC (Non-Small Cell Lung Cancer).